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Abstract
The accurate detection of low-allelic variants is still challenging, particularly for the identifi-
cation of somatic mosaicism, where matched control sample is not available. High through-
put sequencing, by the simultaneous and independent analysis of thousands of different
DNA fragments, might overcome many of the limits of traditional methods, greatly increas-
ing the sensitivity. However, it is necessary to take into account the high number of false
positives that may arise due to the lack of matched control samples. Here, we applied deep
amplicon sequencing to the analysis of samples with known genotype and variant allele
fraction (VAF) followed by a tailored statistical analysis. This method allowed to define a
minimum value of VAF for detecting mosaic variants with high accuracy. Then, we exploited
the estimated VAF to select candidate alterations in NF2 gene in 34 samples with unknown
genotype (30 blood and 4 tumor DNAs), demonstrating the suitability of our method. The
strategy we propose optimizes the use of deep amplicon sequencing for the identification of
low abundance variants. Moreover, our method can be applied to different high throughput
sequencing approaches to estimate the background noise and define the accuracy of the
experimental design.
Introduction
Mosaicism has been defined as the simultaneous presence, in a single individual, of two or
more cell populations with different genotypes arising from the same fertilized egg. It is in-
volved in more than 30 monogenic disorders showing variable expressivity according to the
amount of mutated cells [1]. The occurrence of mosaicism depends on the disorders and its
real frequency could be underestimated because of ascertainment bias, i.e. a low level of
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mosaicism in leucocytes might remain undetected if the molecular analysis is limited to blood
cell DNAs.
Mosaicism is a frequent occurrence in Neurofibromatosis type 2 (NF2, MIM 101000) [2–4],
a tumor predisposition syndrome characterized by the development of bilateral vestibular
schwannomas, often associated with other schwannomas of cranial and spinal nerves, as well
as meningiomas and ependimomas [5–7].
NF2 is an autosomal dominant disorder caused by alterations in the NF2 tumor suppressor
gene (MIM 607379), located in 22q12 [8, 9]. Germline variants of NF2 are detected in about
91% of familial cases and 45–50% of sporadic ones [2, 3]. Mosaicism has been confirmed in
about 25–33% of de novo NF2 patients [2–4], with the alteration only detected in tumors and
not in DNA from leukocytes, and it could be even more common in sporadic patients with
mild phenotypes [4].
The identification of mosaicism is challenging, but it is a critical point for NF2 patients: the
amount and the distribution of mutated cells affects the clinical phenotype, as well as the trans-
mission risk to offspring. For these reasons, the development of analysis methods for the iden-
tification of low level of mutated alleles is really important. Until now only the identification of
the same NF2 variant in at least two tumors of the patient enables a diagnosis of mosaic NF2,
even if the alteration is not detected in blood DNA.
Recently, alternative methods to increase the sensitivity in detecting low amount of mutated
alleles have been developed. High Resolution Melting Analysis (HRMA) allows to identify al-
terations in the melting curve of amplicons even if the variants are unknown and represents a
very sensitive approach to detect low percentages of mutated cells in blood DNA [10, 11].
However this approach does not permit to characterize the specific alteration. The variant
must be identified by Sanger sequencing that has a detection limit of about 10% of mutated al-
lele [11]. The alternative to clone the PCR product in plasmid vectors, amplifying the plasmids,
and sequencing the individual clones is too laborious to be used in a routinely diagnostic prac-
tice. Digital PCR greatly increases the sensitivity in revealing low level of mutated alleles using
an emulsion quantitative real time PCR with two fluorescent probes specific for wild type or
mutated allele, respectively [12]; however, a priori knowledge of the variant is needed. Finally,
COLD PCR [13] and ICE-COLD PCR [14] approaches were used to selectively amplify mutat-
ed alleles present in low percentage in genomic DNA. By using a lower denaturing temperature
it is possible to preferentially denature and amplify the minority allele and detect it by direct se-
quencing of the corresponding amplicon even if its percentage is lower than 10% [15]. Howev-
er, as for digital PCR, these techniques are strictly subordinate to the knowledge of position
and type of the variant.
High throughput sequencing may overcome the problem. Over the last few years, next-gen-
eration sequencing (NGS) has become a popular strategy for genotyping, enabling more precise
variant detection compared to traditional methods due to its high resolution and high through-
put. The simultaneous and independent analysis of hundreds or thousands of DNA fragments,
allows low abundance variants to become readily detectable; on the other hand, the identifica-
tion of the exact type of alteration allows to use other techniques, such as digital, COLD and
ICE-COLD PCRs, to verify the presence of such alterations.
Nevertheless, even with NGS, detecting mosaicism is still challenging, especially for low alle-
lic-fraction variants.
Several factors affect the sensitivity and specificity of low level allelic-fraction variant calls
along the genome, including the depth of sequence coverage, the local sequencing error rate,
the allelic fraction of the variant and the evidence thresholds used to declare a variant [16]. The
read depth necessary to accurately detect a variant is dependent on the prevalence of the mu-
tant allele. Targeted panel sequencing, and in particular amplicon sequencing, has been widely
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used to increase single nucleotide variation (SNV) detection sensitivity by achieving a high me-
dian read depth, even on a bench top sequencer. At the moment this experimental design is the
best suitable approach to meet the critical needs of high sensitivity and specificity in the detec-
tion of low level allelic-fraction [17, 18].
To date, specific bioinformatic methods for the detection of somatic mosaic variants have
not been estabilished, although several methods have been developed to identify somatic vari-
ants in tumor tissues (which are, similarly to the mosaic ones, low level allelic fraction vari-
ants). In general, these methods belong to two groups: 1) independent analysis for tumor and
normal datasets from an individual, 2) simultaneous analysis for matched tumor and normal
datasets using joint probability-based statistical approaches.
The comparison of matched tumor and germline samples is crucial not only to distinguish so-
matic from germline variants but also to bring out low allelic-fraction from background noise
caused by high sequencing error rate. So far, methods developed to identify tumor-associated
variants have not been tested for the identification of somatic mosaicism, where matched control
sample is absent. For this reason, the use of tumor-associated somatic variants detection methods
in single sample mode leads to the identification of a large number of false positive events [16].
This manuscript describes the strategy used to identify low allelic-fraction variants in NF2
gene by deep sequencing approach followed by tailored bioinformatic analysis.
Materials and Methods
Patients and Calibration samples
Constitutional DNA samples were obtained from peripheral blood leukocytes.
DNA was extracted from blood leukocytes and from fresh frozen tumor tissue using stan-
dard procedures with phenol/chloroform extraction and ammonium acetate/
ethanol precipitation.
To evaluate the diagnostic sensitivity of Illumina Miseq platform and its ability to identify
mosaicism in DNA samples, we performed serial dilutions of a wild-type DNA with genomic
DNA deriving from five non-mosaic NF2 patients carrying five different NF2 variants.
Each patient DNA sample was mixed with wild type DNA to obtain 3 calibration samples
containing 10%, 5% and 1% of mutated allele, respectively. Each calibration sample was pre-
pared in duplicate. In addition, 8 known mosaic patients were also analyzed; they had been
identified by Sanger sequencing of multiple tumors of each patient while blood DNAs sequenc-
ing did not confirm the variants found in tumor tissues in any of the patients.
Finally, we screened by deep sequencing a total of 34 consecutive DNA samples (4 tumor
and 30 blood DNAs) referred to our laboratory for NF2mutational analysis. Fifteen patients
had a NF2 clinical diagnosis based on the current diagnostic criteria [19–21]; the others had
multiple schwannomas and/or meningiomas and/or ependimomas or 1 central nervous system
tumor associated with juvenile cataract and/or cafè-au-lait spots (S1 Table). All the patients an-
alyzed have been previously screened by MLPA analysis to exclude genomic rearrangements.
Data of the study (variants and phenotypes) were submitted at the Leiden Open Variation
Database (LOVD; URL: http://lovd.nl/3.0/home).
Written informed consent was obtained from all subjects. The study was approved by the
ethical committee of Careggi Hospital.
Amplicon design and sequencing
Our amplicon design included NF2 and SMARCB1(MIM 601607; NM_003073.3) genes; this
choice was made for two main reasons: i) to increase the number of variants present in the cali-
bration samples, and, ii) to use the same amplicon design to detect SMARCB1mutations in
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two other hereditary diseases, namely schwannomatosis (MIM162091) and Rhabdoid Tumor
Predisposition Syndrome (MIM609322).
Selection of NF2 and SMARCB1 regions of interest (UTR+CDS) was performed by TruSeq
Custom Amplicon (TSCA) protocol. Amplicons were designed by Illumina DesignStudio
(http://www.illumina.com). A total of 44 amplicons of an average of 250 bp in length compris-
ing about 5581 bp was obtained (100% on-target coverage). Library preparation was performed
using the TruSeq Custom Amplicon Library Preparation Kit v1.5 (Illumina, San Diego, CA,
USA). The genomic DNA input for amplicon library preparation was 250 ng for each sample
according to manufacturer’s instructions. All sample libraries were equimolarly pooled and se-
quenced on the Illumina MiSeq Sequencer (Illumina, San Diego, CA, USA) with MiSeq Re-
agent Kit v2 (2X150 cycles) according to the manufacturer’s instructions.
Data analysis and processing
Amplicon reads were aligned against the human reference genome hg19 with BWAMEM [22].
Alignments were soft-clipped based on forward and reverse primers length and position in
each read by custom scripts. GATK version 2.5.2 [23] was used to recalibrate base qualities and
realign aligned reads around indels. Regions with coverage less than or equal 100x in more
than 50% of samples (low-coverage regions) were discarded for downstream analyses. A mosa-
ic variant analysis was applied to detect low abundance variants: SNVs were identified using
MuTect version 1.1.4 [16] with standard parameters and GATK IndelGenotyperV2 (with min-
Fraction = 0.001 and minCnt = 3) was used to detect InDels. Genomic and functional annota-
tion of detected variants was made by Annovar [24].
Coverage statistics was performed by DepthOfCoverage utility of GATK. BASH and R cus-
tom scripts were used to obtain the list of low coverage (100X) regions per sample.
Statistical measures
A Receiver Operating Characteristic (ROC) curve analysis was used to estimate the variant al-
lele fraction (VAF) to obtain the best detection accuracy for low level mosaicism identification.
To this end, the known variants of calibration samples (Table 1) were exploited to perform this
analysis. For each variant type analysis (SNVs and InDels) and for each calibration sample we
estimated True Positive Rate (TPR) and False Positive Rate (FPR) at step i (i-th value of
threshold parameter, that is VAF) as:
TPR i ¼
TPi
TP
¼ detection sensitivity
FPR i ¼
FPi
FP
¼ 1 detection specificity
where TPi and FPi are respectively the number of true and false positive variants with VAF
VAFi while TP and FP are the total number of true and false positives (TP + FP is the total
number of detected variants). Detection accuracy was estimated by measuring the Area Under
the Curve (AUC) inferred from the ROC curves.
Standard PCR and HRMA Conditions
PCR reactions were performed in 20 ul, with 2uL 10X PCR buffer containing 1.5mMMgCl2
(Qiagen, Hilden Germany), 0.25 mM of each dNTP, 0.5 uM of forward and reverse primers,
0.5U HotStarTaq Plus (Qiagen, Hilden, Germany) and 100 ng of genomic DNA. SYTOs 9
(Invitrogen, Eugene, Oregon, USA) was used as the intercalating dye in HRMA. PCR condition
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consisted of an initial denaturation step at 95°C for 5 min, following by 35 cycles of denaturing
at 95°C for 30 sec, 30 sec at annealing temperature and elongation at 72°C for 30 sec. The final
extension was carried out at 72°C for 20 min for HRMA and 10 min for sequencing analysis.
HRM analysis was performed on the “Rotor Gene 6000 Instrument” (Corbett Research,
Sydney, Australia). Amplified products were denaturated at 95°C for 1 min and then rapidly
cooled to 40°C for 1 min in order to facilitate heteroduplex formation. Melt curve data for each
PCR product were acquired in a wide temperature range (75°C to 95°C), at a ramping rate of
0.1°C/sec. Results were analyzed as fluorescence versus temperature graphs.
COLD PCR
To design a COLD-PCR assay a new reduced denaturation temperature for the reactions was
determined (Tc). The melting temperature (Tm) of a given amplicon was firstly identified via
HRMA of conventional PCR using an intercalating dye: the Tc is usually 1°C below the experi-
mentally derived Tm. Subsequently, a set of COLD-PCR reactions at graded temperatures
below the Tm were performed, in order to identify the optimal Tc.
Fast COLD-PCR was used for the detection of Tm-decreasing variants and its cycling condi-
tions were as follow: 95°C for 5 min; 20 cycles of 95°C for 30 sec, primer annealing temperature
for 30 sec, 72°C for 30 sec; then 30 cycles of Tc for 3 sec, primer annealing temperature for
30 sec, 72°C for 30 sec; and final extension at 72°C for 10 min.
Full COLD-PCR protocol was applied for identifying Tm-increasing or-not modifying
variants using the following conditions: denaturation at 95°C for 3 min, 25 cycles of 95°C for
15 sec, primers annealing temperature for 30 sec, 72°C for 1 min; then 30 cycles of 95°C for
15 sec, 70°C for 8 min, Tc for 3 sec, primers annealing temperature for 30 sec, 72°C for 1 min,
and final extension at 72°C for 20 min. COLD-PCR assays were performed using the same
final reagent concentration used in standard PCR. Primers sequences are available on request.
Sanger Sequencing
PCR and COLD-PCR products were purified using HiYieldGel/PCR DNA Fragments
Extraction Kit (RBCBioscience, New Taipei City, Taiwan). Sequencing analysis was performed
on both strands using the BigDye Terminator v1.1 Cycle Sequencing Kit (Life Technologies
Applied Biosystems, Austin, Texas, USA) and a model 310 automated sequencer (Life
Table 1. Known variants present in calibration samples.
Genea Position(HG19) Variantb Samples VariantType Annotation
NF2 chr22:30000057 c.70_71insT 164 InDel Frameshift insertion
NF2 chr22:30032783 c.158_165del 277 InDel Frameshift deletion
NF2 chr22:30032794 c.169C>T 407 SNV Stopgain
NF2 chr22:30050660 c.462delC 82 InDel Frameshift insertion
NF2 chr22:30050662 c.464C>T 82 SNV Nonsynonymous
NF2 chr22:30051658 c.592C>T 67 SNV Stopgain
SMARCB1 chr22:24129129 c.-228G>T 277 SNV rs11704810
SMARCB1 chr22:24129240 c.-117C>T 164, 67 SNV rs11090285
SMARCB1 chr22:24167513 c.897G>A 277 SNV rs2229354
SMARCB1 chr22:24176480 c.*113_*114insG 277 InDel rs146383610
a: NF2: NM_181832.2; SMARCB1:NM_003073.3
b: The DNA variant numbering is based on cDNA sequences for both genes, with the A of the ATG translation-initiation codon numbered as +1.
doi:10.1371/journal.pone.0129099.t001
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Technologies Applied Biosystems). Variant nomenclature follows the Human Genome Varia-
tion Society recommendations (http://www.hgvs.org). The DNA variant numbering is based
on the NF2 cDNA sequences (GenBank accession number NM_181832.2) with the A of the
ATG translation-initiation codon numbered as +1.
Multiplex Ligation Probe Amplification
Copy number changes (deletions or duplications) of NF2 locus and flanking genes were ana-
lyzed by Multiplex Ligation-Dependent Probe Amplification (MLPA), using NF2 and/or 22q11
MLPA test kits (MRC-Holland, P044_B1 and P324_A2). Electrophoresis data were analyzed
by GeneMapper software (Life Technologies, Carlsbad, CA, USA).
Results
Coverage statistics
Amean number of 118842 reads were obtained for each sample. The mean median coverage
per sample was 1121X ranging from 14X to 2045X (S2 Table and S1 Fig). Low-coverage regions
represented a total of 467 bp (8.4% of target regions); however, the majority of them matched
to intronic or UTR regions (346 bp, 75% of low-coverage regions), characterized by high GC
content.
Low-coverage regions involving CDSs were a total of 121 bp: these included segments of
exon 1 and exon 5 of SMARCB1 and represented 4% of the total CDSs (2925 bp) of our design.
Calibration samples analysis
Calibration samples were used to estimate the minimum Variant Allele Fraction (VAF) to
reach the best analysis accuracy. S2 Fig reports the boxplots representing the correlation
(R = 0.99) between expected and observed VAF. S3 Fig shows the electropherogram obtained
by Sanger sequencing of the serial dilutions of the Calibration samples.
To understand the performance of our data analysis pipeline, we applied the mosaic variant
analysis to calibration samples. Results for each calibration sample, summarized in S3 Table,
show that False Positives (FPs) represent the great majority (~99%) of the detected variants. In
addition, the great majority of them have very low allele frequency: only 10% of all the detected
SNVs and InDels have allele frequency greater than 0.015 and 0.006, respectively (Fig 1A).
Moreover, we observed that detected SNVs are mostly unique among samples: Fig 1B shows
that ~40% of all SNVs are unique (Event recurrence = 1), while only 20% are present in more
Fig 1. Features of false positives events detected in calibration samples. (a) Boxplot of VAFs of events
detected by MuTect (SNVs) and IndelGenotyperV2 (InDels). n is the total number of detected events, n* is
the mean number of events (per sample) with the corresponding standard deviation. (b) Histogram of events
recurrence among calibration samples (n = 30) for SNVs (black) and InDels (grey). Corresponding
cumulative percentages are reported in dashed black (SNVs) and grey (InDels) lines.
doi:10.1371/journal.pone.0129099.g001
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than 5 samples. On the other hand, detected InDels have a quasi-uniform recurrence: 50% of
all of them are recurrent in more than 14 samples (Fig 1B).
In order to improve the accuracy of our analysis, we used the estimated VAFs as threshold
parameter to discriminate between false and true events. To this end, we used the variants de-
tected by MuTect and IndelGenotyperV2, with their respective allele frequency, to perform a
ROC curve analysis. To avoid introducing systematic errors in estimating statistical measures,
recurrent events across all the calibration samples were discarded for downstream analysis.
These events correspond to two InDels that have the same VAF in all the calibration samples,
even for different dilutions (S4 Table). Fig 2 shows results of ROC curve analysis: for both
SNVs (Fig 2A) and InDels (Fig 2B), we obtained a high accuracy for calibration samples with
dilution equal to 5% and 10%, while detecting variants with VAF~1% remained challenging.
This is also shown in Table 2 that reports the statistical measures estimated from ROC
curve analysis. At the estimated cut-off value, in samples with dilution 5% and 10% we are able
to detect all the events (TPR> 0.99), drastically reducing the number of FPs events. On the
contrary, in samples at 1% dilution, variants could be detected at the cost of specificity. In par-
ticular, we identified 15/22 variants (8/14 SNVs and 7/8 InDels), corresponding to a
TPR = 0.55 for SNVs and TPR = 0.92 for InDels at the best VAF cut-off. In this case, we ob-
tained about 5 false SNVs and 3 false InDels per sample.
Selection of candidate variants
ROC analysis results in calibration samples were exploited to select candidate mosaic variants
in samples with unknown genotype. In particular, we used the estimated cut-off VAFs to filter
detected variants. In order to control specificity, we required to obtain< 2 FP events (1 SNV
and 1 InDel) per sample. This corresponds to select a cut-off VAF equal to 1.6% for both SNVs
and InDels in all the ROC curves, irrespective of dilution (false positives are independent from
dilutions). With this VAF value, we obtained TPR = 0.25 (for SNVs) and TPR = 0.58 (for
InDels) in samples with dilution 1% and TPR> 0.99 for both SNVs and InDels in samples
with dilution 5%.
Candidate variants were selected following the next step by step exclusion criteria:
1. variants included in dbSNP database or in 1000g project with frequency higher than 1%;
2. recurrent variants identified in more than 5 patients;
3. variants with VAF lower than 1.6%;
Fig 2. ROC curve analysis of variants found in calibration samples. ROCCurve analysis for SNVs (a)
and InDels (b) events. Data are obtained by averaging results of calibration samples with the same dilution.
Cross, triangle and circle points are relative to 1%, 5% and 10% dilution degree. Data do not contain
recurrent events.
doi:10.1371/journal.pone.0129099.g002
Deep Amplicon Sequencing for the Detection of NF2 Somatic Mosaicism
PLOSONE | DOI:10.1371/journal.pone.0129099 June 12, 2015 7 / 15
4. non synonymous variants predicted to be non-deleterious by at least two out of three open
access prediction software questioned (PolyPhen 2, SIFT and Mutation Taster);
5. variants identified in samples carrying a pathogenetic variant confirmed by
Sanger sequencing
The list of the candidate variants is reported in Table 3.
Validation of verified mosaic patients
Verified mosaic patients were analyzed to confirm the presence and the VAF of each alteration.
Our bioinformatic analysis correctly identified the variants in 6 out of 8 known mosaic sam-
ples. 7 blood DNAs showed VAF values under the Sanger sequencing detection limit, ranging
from 8.7 to 1.95% (Table 3). In sample 106, the variant c.130_133delAAGGinsCACACGGG
CGGC was identified with a VAF value of 14.5%; however, direct sequencing in blood DNA
did not detect this alteration, maybe due to its complexity. Considering the high sensitivity of
our method in detecting mosaic variants, the two remaining patients, whose mosaic diagnosis
was made by the analysis of multiple tumors, likely, do not carry the alterations in blood cells.
Sanger sequencing validation of NF2 variants in samples with unknown
NF2 genotype
A total of 34 samples with unknown NF2 genotype (30 blood DNAs and 4 tumor DNAs) were
analyzed. Results obtained after filtering with the established VAF of 1.6% and the functional
criteria, are reported in Table 3. Although its very low mean coverage, sample 465 was not ex-
cluded because we found a pathogenetic variant with high VAF (~ 39%), confirmed by
direct sequencing.
NF2 deleterious variants were identified in 6 out of 30 blood DNA samples (Table 3). Five
DNA samples with a VAF 10%, were direct sequenced and variants were confirmed in all of
them. Blood DNA sample from the last patient (410) showed a low abundance variant at deep
sequencing analysis: the c.459C>A variant was detected with VAF of 2.4%. Direct sequencing
of genomic DNA did not reveal any alteration; however, the sample showed a melting profile
alteration in exon 5, at HRMA. Using fast COLD-PCR protocol, the mutated allele was selec-
tively amplified as much as necessary to confirm the alteration using sequencing analysis
(Fig 3).
We found NF2 deleterious variants, confirmed by Sanger sequencing, in the four NF2-asso-
ciated tumors (Table 3). Three tumors (T819, T820, T821) from patient 498, showed the same
NF2 variant, confirming it as a germline alteration. In the tumor DNAs, VAF (77.4%–82.8%)
Table 2. Results of ROC curve analysis on calibration samples.
Variant type Dilution Best VAF cut-off FPRa TPRa Area under the ROC curve Number of FPsb
SNV 0.01 0.01 0.26 0.55 0.5 5.5
0.05 0.03 0.02 > 0.99 > 0.99 0.41
0.1 0.06 0.01 > 0.99 > 0.99 0.28
InDel 0.01 0.01 0.02 0.92 0.91 2.8
0.05 0.05 < 0.01 > 0.99 > 0.99 < 0.01
0.1 0.08 < 0.01 > 0.99 > 0.99 < 0.01
a TPR and FPR are calculated from ROC curves at the best VAF cut-off. This data do not contain recurrent events.
b The number of FPs at each cut-off value was estimated by the product of FPR and the number of detected variants per sample
doi:10.1371/journal.pone.0129099.t002
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Table 3. Sample results obtained by filtering on the basis of VAF cut-off and functional criteria.
Sample Type Diagnosis Median
Coverage
Total
InDels
Total
SNVs
VAFfiltered
InDels
VAFfiltered
SNVs
Candidate variantsb VAF
(%)
Sanger
sequencing
validation
11 B mosaic
NF2
813 159 18 1 2 - -
65 B mosaic
NF2
442 81 12 3 2 c.193C>Tc 2.03 -
106 B mosaic
NF2
1092 200 19 2 2 c.130_133del4insCACACGGGCGGCc 14.5 -
134 B mosaic
NF2
960 180 15 2 1 c.169C>Tc 7.5 -
144 B mosaic
NF2
1289 214 30 0 1 c.586C>Tc 1.95 -
241 B mosaic
NF2
628 109 21 1 4 c.592C>Tc 3.7 -
295 B mosaic
NF2
891 174 19 3 2 c.1396C>Tc 8.7 -
428 B mosaic
NF2
908 172 21 3 4 - - -
410 B NF2 960 227 35 1 6 c.459C>A 2.4 YESd
451 B NF2 1388 215 38 1 4 - - -
465 B NF2 14 4 4 2 3 c.675+1G>T 39 YES
472 B NF2 419 70 8 5 2 c.41_42del 19.2 YES
474 B NF2 1243 179 28 1 1 - - -
481 B NF2 728 146 17 1 2 c.52C>T 53.8 YES
484 B NF2 1176 220 24 1 0 - - -
488 B NF2 798 130 21 0 2 - - -
489 B NF2 1363 193 20 0 0 - - -
491 B NF2 1494 235 26 1 2 - - -
493 B NF2 728 143 12 2 1 - - -
496 B NF2 1092 194 17 0 3 - - -
500 B NF2 2045 282 26 2 1 - - -
498 B NF2 1494 248 42 2 3 c.448-2A>G 60 YES
492 B NF2 1388 244 27 3 5 - - -
483 B Uncertain 1033 220 21 4 1 c.916delC 50 YES
445 B Uncertain 1764 264 25 2 3 - - -
453 B Uncertain 1522 228 38 2 4 - - -
454 B Uncertain 859 163 17 1 3 - - -
462 B Uncertain 1033 203 23 3 3 - - -
463 B Uncertain 1289 232 15 2 4 - - -
469_A B Uncertain 1522 259 35 4 1 - - -
469_B B Uncertain 1388 244 25 2 4 - - -
470 B Uncertain 996 190 12 0 2 - - -
471 B Uncertain 1414 218 18 1 3 - - -
478 B Uncertain 1700 228 27 1 1 - - -
479 B Uncertain 813 138 19 1 2 - - -
495 B Uncertain 1764 249 18 1 3 - - -
497 B Uncertain 1831 255 29 0 5 - - -
503 B Uncertain 891 158 23 4 3 - - -
T754 T NF2 1176 219 18 0 3 c.532C>T 29.2 YES
(Continued)
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was substantially higher than the corresponding blood DNA. Indeed, at MLPA, the three tu-
mors showed partial loss of 22q, involving the NF2 gene.
The last tumor (T754) showed the c.532C>T variant, with a VAF of about 29%. This result
is consistent with the maintenance of both copies of 22q, confirmed by MLPA analysis.
Evaluation of variants with VAF lower than 1.6%
In order to assess whether the set VAF threshold would avoid losing detectable variants, we
also evaluated variants with VAF< 1.6%. On the basis of the functional and clinical criteria,
we selected two deleterious variants, identified in two different patients, 451 and 500.
In patient 451, the c.118A>T variant in exon 2 of NF2 gene was pointed out with VAF of
1%. COLD PCR was optimized for detection of this alteration, using the full protocol, because
the substitution A>T do not modify the melting temperature of the amplicon. However, the al-
teration was not confirmed by Sanger sequencing.
Table 3. (Continued)
Sample Type Diagnosis Median
Coverage
Total
InDels
Total
SNVs
VAFfiltered
InDels
VAFfiltered
SNVs
Candidate variantsb VAF
(%)
Sanger
sequencing
validation
T819 T NF2 828 139 11 2 2 c.448-2A>G 77.4 YES
T820 T NF2 1092 184 20 4 2 c.448-2A>G 82.8 YES
T821 T NF2 828 159 12 3 1 c.448-2A>G 78 YES
a: B: blood; T: tumor.
b:The DNA variant numbering is based on the NF2 cDNA sequences (GenBank accession number NM_181832.2) with the A of the ATG translation-
initiation codon numbered as +1.
c: Variants already characterized.
d: COLD-PCR protocol.
doi:10.1371/journal.pone.0129099.t003
Fig 3. Validation of NF2 variant in an unknown NF2mosaic patient. The c.459C>T variant in exon 5 of
theNF2 gene was identified by deep sequencing. A) 410 DNA sample differed appreciably from wild-type
melting curves at HRMA analysis; but the alteration was not detectable by Sanger sequencing after standard
PCR (B). C) COLD-PCR allowed to enrich the variant allele as much as necessary to make the alteration
clearly visible by Sanger sequencing.
doi:10.1371/journal.pone.0129099.g003
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Patient 500 blood DNA showed the variant c.1396C>T, with VAF of 1% and direct se-
quencing of genomic DNA did not detect the alteration. COLD PCR conditions for
c.1396C>T were previously optimized [15]. However, COLD PCR approach did not identify
any alteration by Sanger sequencing.
Discussion
Mosaicism is a frequent event (25–30%) in NF2 sporadic cases. The identification of mosaic
variants in lymphocyte DNA of NF2 patients has important clinical implications and can opti-
mize disease management. Indeed, the molecular diagnosis of these cases is fundamental to im-
prove genetic counseling, mainly providing the chance to perform prenatal diagnosis.
Rapid advances in NGS technologies, together with the development of powerful computa-
tional tools, have open new scenarios in detecting mosaic variants. Amplicon sequencing can
be used to increase low frequency fraction variant detection sensitivity by achieving a much
higher read depth [25]. Nevertheless, the accurate detection of low-allelic variants is still chal-
lenging, particularly for the identification of somatic mosaicism, where matched control sam-
ple is absent.
To assess the capability in detecting low abundance variants in blood DNA, we screened by
amplicon deep sequencing the UTRs and coding regions of NF2 in a set of DNA samples re-
ferred to our laboratory with a medical request for NF2molecular analysis. MuTect and Indel-
GenotyperV2 were used to detect mosaic SNVs and InDels, respectively, and a ROC curve
analysis was applied to estimate the minimum variant allele fraction (VAF) to obtain the best
detection accuracy of low level mosaicism.
To figure out the accuracy of the method, we applied our data analysis pipeline for the de-
tection of pathogenic variants in 30 calibration samples with known variants and VAF. We
considered 10 different variants in 5 independent samples (Table 1), for a total of 42 SNVs and
24 InDels in all the calibration samples (different dilutions and replicates). Regarding sensitivi-
ty, we were able to identify 100% of the 46 known variants in samples with dilutions 5%. On
the other hand, detecting events in samples with dilution 0.01 was challenging: we identified
only 62% of the variants. Undetected variants either fall in amplicons with lower coverage or,
even if they are supported by a high number of reads, their allele fraction is low (~0.01) (S5
Table). The latter case involves only SNVs events and is likely due to the downsampling strate-
gy of MuTect. Regarding specificity, we had a large number of false detections (an average of
19 and 168 FPs for SNVs and InDels per sample, respectively) which constituted the great ma-
jority (> 99%) of all the detected variants.
Recently, Chen et al. [26] used a strategy based on calibration samples to identify low-level
mosaic RB1 variants in sporadic retinoblastoma cases. However, they did not report any evalu-
ation on the detection accuracy of their method; in particular, data on the number of detected
false positive events were missed. Our data show that estimating specificity in low level variants
detection is fundamental to discern between true mosaicism and false events. For this reason,
we studied the features of false positives identified in calibration samples. We observed (Fig
1A) that FPs had low VAF. Moreover, false InDels tend to be recurrent among different sam-
ples (Fig 1B). ROC curve analysis of calibration samples (Fig 2 and Table 2) allowed us to de-
termine the VAF value that gave the best trade-off between sensitivity and specificity (best
accuracy). We obtained very high accuracy in detecting variants with VAF 5%, while we
found challenging to accurately detect variants with VAF~1%: for samples with dilution 1% at
the estimated cut-off value of VAF we obtained 8 false detections that may be harder to vali-
date, especially in diagnostic settings. For this reason, we selected a VAF cut-off to get< 2 FPs
(1 for SNVs and 1 for InDels) per sample, obtaining VAF = 1.6 for both SNVs and InDels.
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On the basis of the statistical results and functional criteria, we filtered the data from 34
samples with unknown NF2 genotype (30 blood DNAs and 4 tumor DNAs) to identify causa-
tive alterations. A total of 6 variants were identified in blood DNAs with VAF ranging from
2.4% to 60%. DNA alterations with VAF higher than 10% were confirmed by direct sequenc-
ing. Moreover, we were able to detect causative NF2 alterations in the analyzed tumors with
VAF values consistent with the results obtained fromMLPA analysis.
OurNF2 variants detection rate in patients with a clear NF2 clinical diagnosis resulted of 33%.
NF2 pathogenic alterations (point mutations and genomic rearrangements) can be found in
about 45–55% of sporadic patients with bilateral vestibular schwannoma [2, 3]; considering
that our group of patients had been previously analyzed by MLPA to rule out the presence of
genomic rearrangements (10–15% of the NF2 alterations), our detection rate is consistent with
data from the literature.
In patient 410, deep sequencing identified the c.459C>A variant inNF2 exon 5 with VAF of
2.4%. The low abundance alteration had not been detected by the analysis methods previously used:
HRMA and Sanger sequencing of the coding and flanking regions ofNF2. Patient 410 shows clini-
cal features consistent with a diagnosis of mosaic NF2: bilateral vestibular schwannomas, one hypo-
glossal schwannoma and one falx cerebri meningioma, without involvement of peripheral nerves.
The discovery, by deep sequencing, of theNF2 pathogenic alteration in the patient allowed to set
and optimize the COLD PCR conditions to enrich the minority allele, confirming the presence of
the alteration by direct sequencing analysis. This result demonstrates that deep sequencing analysis
associated to method for detecting low abundance variants, such as COLD- or Digital- PCR, may
represent a suitable approach for increasing the diagnostic throughput in detecting mosaicism.
To evaluate if candidate variants with VAF< 1.6% could be detected by COLD PCR, we an-
alyzed two potentially pathogenic variants, with VAF about of 1%, identified in two different
patients. COLD PCR conditions were optimized for both variants, but none of them was veri-
fied by direct sequencing. This result confirmed that, in our experimental design, we could not
discriminate between false or true positive variants for alterations with VAF< 1.6%. Likely,
more sensitive methods, such as Digital PCR [27], could detect variants with lower VAF; how-
ever, the number of candidate alterations sharply increase when variants with VAF< 1.6% are
included: about 8 variants (InDels and SNVs) per sample are found when the cut-off VAF is
set at 1%. Optimizing conditions for COLD or Digital PCR is time consuming and the costs
might become prohibitive if 8 alterations per sample have to be validated. Moreover, depending
on their localization and type, some variants may still remain unconfirmed [13].
Noteworthy, the VAF cut-off used in this work is strictly related to our experimental design
but the procedure we used is not. Actually, the method we propose (sequencing of serial dilu-
tions of samples with known variants, followed by ROC curve analysis) is useful to define the
VAF cut-offs when planning a study to detect low abundance variants, even though different
NGS platforms and bioinformatic tools in investigating different genomic regions may lead to
different performance in terms of detection accuracy.
In conclusion, the proposed method may be useful for optimizing every deep sequencing exper-
imental plan. Indeed, regardless of the experimental design, the use of calibration samples followed
by tailored statistical analysis enables to estimate the minimum allele fraction detectable with high
accuracy, or, in other terms, to evaluate the background noise of deep sequencing analysis.
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